Incretins as a novel therapeutic strategy in patients with diabetes and heart failure.

Heart Failure Reviews
M A KhanM A Mamas

Abstract

Heart failure (HF) and diabetes mellitus (DM) commonly co-exist, with a prevalence of DM of up to 40 % in HF patients. Treatment of DM in patients with HF is challenging since many of the contemporary therapies used for the treatment of DM are either contraindicated in HF or are limited in their use due to the high prevalence of co-morbidities such as significant renal dysfunction. This article presents an overview of the physiology of the incretin system and how it can be targeted therapeutically, highlighting implications for the management of patients with DM and HF. Receptors for the incretin glucagon-like peptide-1 (GLP-1) are expressed throughout the cardiovascular system and the myocardium and are up-regulated in HF. GLP-1 therapy improves cardiac function in animal models of HF through augmented glucose uptake in the myocardium mediated through a p38 MAP kinase pathway. Small clinical studies have shown that GLP-1 improves ejection fraction, reduces BNP levels and enhances functional capacity in patients with chronic HF. A number of randomized controlled trials are currently underway to define the utility of targeting the incretin system in HF patients with DM. Incretin-based therapy may represent a novel therapeutic st...Continue Reading

References

Jul 1, 1974·The American Journal of Cardiology·W B KannelW P Castelli
Aug 1, 1971·Canadian Journal of Biochemistry·J C Brown, J R Dryburgh
Dec 1, 1967·The Journal of Clinical Investigation·M J Perley, D M Kipnis
Aug 15, 2001·The Journal of Clinical Endocrinology and Metabolism·M B Toft-NielsenJ J Holst
Jan 31, 2003·Cardiovascular Diabetology·Christophe BautersPascal de Groote
Oct 1, 1964·The Journal of Clinical Endocrinology and Metabolism·H ELRICKY ARAI
Oct 19, 2004·Journal of the American College of Cardiology·Justin EzekowitzUNKNOWN APPROACH Investigators
Jun 7, 2005·Journal of the American Society of Nephrology : JASN·Jean-François Yale
Nov 25, 2005·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Inga ThrainsdottirLars Rydén
Nov 30, 2005·European Journal of Clinical Investigation·F CacciatoreF Rengo
Feb 21, 2006·The Journal of Pharmacology and Experimental Therapeutics·Tingcun ZhaoRichard P Shannon
Sep 27, 2006·European Heart Journal·Markku S NieminenUNKNOWN Heart Failure Association, European Society of Cardiology
May 15, 2007·Gastroenterology·Laurie L Baggio, Daniel J Drucker
Aug 4, 2007·Diabetic Medicine : a Journal of the British Diabetic Association·J S ShawE S Kilpatrick
Sep 1, 2007·BMJ : British Medical Journal·Dean T EurichJeffrey A Johnson
Apr 22, 2008·European Heart Journal·Michael R MacDonaldJohn J V McMurray
Dec 17, 2008·Pharmacological Reviews·Wook Kim, Josephine M Egan
May 16, 2009·Nature Reviews. Endocrinology·Julie A Lovshin, Daniel J Drucker
Jun 2, 2009·The American Journal of Medicine·David M KendallRichard M Bergenstal
Jul 22, 2009·Cardiovascular Diabetology·Enrique Z Fisman, Alexander Tenenbaum
Jan 19, 2010·American Journal of Physiology. Heart and Circulatory Physiology·Mads HalbirkHenrik Wiggers
Feb 2, 2010·European Heart Journal·Michel KomajdaPhilip D Home
Mar 11, 2010·Diabetes Care·John B BuseUNKNOWN DURATION-1 Study Group
Aug 28, 2010·Journal of Cardiac Failure·Mamas A MamasLudwig Neyses
Oct 20, 2010·European Journal of Cardiovascular Nursing : Journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology·Christi DeatonSarah Williams

❮ Previous
Next ❯

Citations

Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Dec 17, 2014·Current Problems in Cardiology·Alessandra Dei CasJaved Butler
Aug 27, 2015·Marine Drugs·Yusrizam SharifuddinSiew-Moi Phang
Oct 18, 2014·Current Heart Failure Reports·Amanda R Vest
Jul 16, 2016·European Heart Journal. Cardiovascular Pharmacotherapy·Faiez ZannadGonzalo Calvo
Jul 5, 2017·The Journal of Pharmacy and Pharmacology·Hanbing LiLinghuan Li
Apr 12, 2018·Canadian Journal of Physiology and Pharmacology·Yuanfa YaoHanbing Li
Jan 9, 2013·Nature Reviews. Cardiology·André J Scheen
Jan 4, 2018·Expert Review of Cardiovascular Therapy·Shilpa VijayakumarJaved Butler
Feb 13, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Enver KeleszadeAdele Costabile

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Related Papers

Biochimica Et Biophysica Acta
Andrew N Carley, David L Severson
Reviews in Endocrine & Metabolic Disorders
Sihem Boudina, Evan Dale Abel
Drug Design, Development and Therapy
Annalisa CapuanoKatherine Esposito
© 2021 Meta ULC. All rights reserved